LABTEC GMBH - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/189232.xml LABTEC GMBH - Press Releases en xml@emediawire.com xml@emediawire.com 30 APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") Announce the Successful Completion of the Pilot Bioequivalence Study of Their Donepezil RapidFilm™ http://www.prweb.com/releases/2008/02/prweb665773.htm APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") announce the successful completion of the pilot bioequivalence study of their Donepezil RapidFilm™ further confirming the validity and adaptability of this innovative proprietary technology. (PRWeb Feb 1, 2008)

Read the full story at http://www.prweb.com/releases/2008/02/prweb665773.htm

]]> http://www.prweb.com/releases/2008/02/prweb665773.htm Labtec's Next Generation Pain Patch Successful in Clinical Studies http://www.prweb.com/releases/2007/04/prweb521762.htm Labtec's next generation pain patch successful in clinical studies. (PRWeb Apr 27, 2007)

Read the full story at http://www.prweb.com/releases/2007/04/prweb521762.htm

]]> http://www.prweb.com/releases/2007/04/prweb521762.htm First Continuous Combined Hormone Replacement Patch Approved for Marketing in Europe http://www.prweb.com/releases/2007/01/prweb495410.htm First continuous combined hormone replacement patch approved for marketing in Europe. (PRWeb Jan 7, 2007)

Read the full story at http://www.prweb.com/releases/2007/01/prweb495410.htm

]]> http://www.prweb.com/releases/2007/01/prweb495410.htm Fentanyl Patch Developed by Labtec GmbH First Generic to be Approved for Marketing in Canada http://www.prweb.com/releases/2006/10/prweb444573.htm Labtec´s licensee ratiopharm started marketing in Canada a transdermal patch containing fentanyl for treatment of strong chronic pain, which is generic to J&J´s blockbuster Durogesic®. The patch is 1/3 smaller than the originator´s product and is the first generic fentanyl patch to be approved for marketing in Canada. (PRWeb Oct 1, 2006)

Read the full story at http://www.prweb.com/releases/2006/10/prweb444573.htm

]]> http://www.prweb.com/releases/2006/10/prweb444573.htm Labtec Begins Phase I Trials for Seven Day Transdermal Sufentanil Patch http://www.prweb.com/releases/2006/07/prweb409499.htm German-based Labtec GmbH has developed Sufentanil TDS, a transdermal patch designed for management of moderate to severe chronic pain. The patch contains the active sufentanil, an opoid drug widely used in anaesthesia, seven times more potent than fentanyl. The extremely small patch based on Labtec´s proprietary matrix technology is designed for seven day use. (PRWeb Jul 12, 2006)

Read the full story at http://www.prweb.com/releases/2006/07/prweb409499.htm

]]> http://www.prweb.com/releases/2006/07/prweb409499.htm APR Applied Pharma Research s.a. and Labtec GmbH Sign New Strategic Partnership for the Development and Licensing of RapidFilm™, an Innovative Drug Delivery Technology http://www.prweb.com/releases/2006/03/prweb360259.htm APR of Switzerland and Labtec of Germany have signed a strategic Cooperation and Partnership Agreement for the development and licensing of the RapidFilm™ Drug Delivery Technology. (PRWeb Mar 17, 2006)

Read the full story at http://www.prweb.com/releases/2006/03/prweb360259.htm

]]> http://www.prweb.com/releases/2006/03/prweb360259.htm